Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Clues to Diabetic Kidney Disease

By HospiMedica staff writers
Posted on 31 Mar 2008
A new study has found that for patients with type I diabetes, increased levels of uric acid in the blood may be an early sign of diabetic kidney disease, appearing before any significant change in urine albumin level, the standard screening test.

Researchers at the Joslin Diabetes Center (Boston, MA, USA) measured serum uric acid concentration in 675 patients with type I diabetes. More...
A medical history and measurements of blood pressure (BP), hemoglobin A1c, albumin excretion rate, and serum concentrations of uric acid and cystatin C were obtained; estimated glomerular filtration rate (GFR) was measured by a cystatin C-based formula.

On screening tests, results showed 311 patients had small amounts of the protein albumin--called microalbuminuria--in the urine. The other 364 patients had normal urine albumin levels. None of the patients had even higher levels of albumin (albuminuria), representing more advanced diabetic nephropathy; in contrast, the serum uric acid level was consistently related to kidney function--the higher the uric acid, the lower the kidney function--and one in five had some impairment of kidney function on a standard GFR test. In univariate and multivariate analyses, lower GFR was strongly and independently associated with higher serum uric acid and higher urinary albumin excretion rate, older age, and antihypertensive treatment. The study was published online ahead of print on February 13, 2008, in the Clinical Journal of the American Society of Nephrology.

"The serum uric acid concentration is modifiable by drugs or by decreasing the intake of dietary protein, the main source of uric acid,” said lead author Elizabeth Rosolowsky, M.D. "If follow-up studies, already underway, demonstrate that serum uric acid concentration predicts the course of early decline in kidney function, then clinical trials would be justified to test whether modifying serum uric acid concentration also modifies the course of renal function decline in type I diabetic patients with high normoalbuminuria or microalbuminuria.”

The association between high serum uric acid and insulin resistance has been known since the early part of the 20th century. Nevertheless, recognition of high serum uric acid as a risk factor for diabetes has been a matter of debate. In fact, hyperuricemia has always been presumed to be a consequence of insulin resistance rather than its precursor. On the other hand, it has been shown that high serum uric acid is associated with higher risk of type II diabetes independent of obesity, dyslipidemia, and hypertension.


Related Links:
Joslin Diabetes Center

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.